Complete Filing Data
Neuphoria Therapeutics Inc. reported Stockholders Equity of $22.01 million for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Neuphoria Therapeutics Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$15.5M | -$21.4M | -$21.8M | -$8.7M | -$7.1M | |
| Research And Development Expense | $9.0M | $9.4M | $13.1M | $16.0M | $5.8M | $5.8M |
| Other Comprehensive Income Loss Tax | $168.5K | $45.2K | $1.0M | |||
| General And Administrative Expense | $7.8M | $8.5M | $8.9M | |||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $168.5K | $45.2K | -$1.0M | |||
| Operating Income Loss | -$1.1M | -$17.9M | -$22.0M | |||
| Operating Expenses | $16.8M | $17.9M | $22.0M | |||
| Nonoperating Income Expense | $291.1K | $2.3M | $462.1K | |||
| Income Tax Expense Benefit | -$468.4K | -$87.3K | -$139.2K | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$838.0K | -$15.6M | -$21.5M | |||
| Comprehensive Income Net Of Tax | -$201.1K | -$15.4M | -$22.4M | |||
| Research And Development Incentive Award | -$299.9K | -$95.2K | -$422.7K | |||
| Deferred Income Tax Liabilities Net | $963.5K | $1.1M | ||||
| Revenue From Contract With Customer Excluding Assessed Tax | $15.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | $1.9M | -$9.9M | $11.3M | -$1.9M | -$804.8K | -$2.8M | -$4.6M | -$5.5M | |
| Research And Development Expense | $697.7K | $3.8M | $1.6M | $1.7M | $1.9M | $1.2M | $2.0M | $3.1M | |
| Other Comprehensive Income Loss Tax | -$570.6K | -$49.2K | $195.8K | $1.3M | -$585.4K | $561.9K | -$451.1K | $63.5K | |
| General And Administrative Expense | $2.1M | $1.9M | $1.4M | $2.6M | $1.7M | $1.2M | $2.5M | $2.4M | |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $570.6K | $49.2K | -$195.8K | -$1.3M | $585.4K | -$561.9K | $451.1K | -$63.5K | |
| Operating Income Loss | -$4.1M | -$5.7M | $12.0M | -$3.7M | -$3.6M | -$2.4M | -$4.6M | -$5.5M | |
| Operating Expenses | $4.1M | $5.7M | $3.0M | $4.4M | $3.6M | $2.4M | $4.6M | $5.5M | |
| Nonoperating Income Expense | $5.9M | -$4.3M | -$796.2K | $1.8M | $2.6M | -$367.7K | -$36.4K | -$39.8K | |
| Income Tax Expense Benefit | -$34.8K | -$34.8K | -$81.2K | $11.6K | -$132.2K | $16.4K | -$34.8K | -$34.8K | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $1.8M | -$9.9M | $11.2M | -$1.9M | -$937.0K | -$2.8M | -$4.6M | -$5.5M | |
| Comprehensive Income Net Of Tax | $2.4M | -$9.9M | $11.1M | -$3.2M | -$219.4K | -$3.3M | -$4.1M | -$5.5M | |
| Research And Development Incentive Award | -$479.0K | $5.2K | -$306.2K | -$271.00 | -$94.7K | ||||
| Deferred Income Tax Liabilities Net | $425.5K | $460.3K | $495.1K | $761.7K | $842.9K | $831.3K | |||
| Revenue From Contract With Customer Excluding Assessed Tax | $15.0M | $662.7K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $22.0M | $39.2M | |||||
| Goodwill | $8.7M | $8.9M | $12.4M | $12.9M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $12.2M | $23.2M | |||||
| Cash And Cash Equivalents At Carrying Value | $12.6M | $12.1M | |||||
| Liabilities | $10.2M | $6.6M | $8.4M | $6.7M | |||
| Assets | $27.6M | $28.6M | $65.3M | $54.3M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$3.0M | -$3.1M | |||||
| Accrued Liabilities And Other Liabilities | $1.5M | $1.2M | |||||
| Retained Earnings Accumulated Deficit | -$178.0M | -$162.5M | |||||
| Restricted Cash | $77.9K | $78.8K | $78.9K | ||||
| Liabilities Current | $3.8M | $2.7M | |||||
| Liabilities And Stockholders Equity | $27.6M | $28.6M | |||||
| Intangible Assets Net Excluding Goodwill | $5.5M | $6.1M | |||||
| Business Combination Contingent Consideration Liability Noncurrent | $587.8K | $2.5M | |||||
| Assets Current | $13.2M | $13.3M | |||||
| Accounts Receivable Net Current | $126.9K | $426.1K | |||||
| Accounts Payable Current | $2.2M | $1.4M | |||||
| Property Plant And Equipment Net | $2.0K | $2.5K | |||||
| Operating Lease Right Of Use Asset | $217.0K | $330.5K | |||||
| Operating Lease Liability Current | $122.0K | $113.9K | |||||
| Common Stock Value | $11.00 | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $1.6M | $505.0K | |||||
| Restricted Cash Noncurrent | $78.8K | $78.9K | |||||
| Other Liabilities Noncurrent | $2.9K | $14.9K | |||||
| Operating Lease Liability Noncurrent | $117.6K | $239.8K | |||||
| Equity | $22.0M | $39.2M | |||||
| Cash And Cash Equivalents | $18.3M | $33.6M | $28.5M | $4.6M | $14.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $29.7M | $12.5M | $19.0M | $26.0M | $13.7M | $17.1M | $17.5M | $17.9M | $19.5M | $17.2M |
| Goodwill | $8.7M | $8.7M | $8.6M | $8.5M | $8.4M | $8.9M | $8.7M | $8.6M | $8.8M | $8.6M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $22.3M | $13.7M | $14.3M | $17.1M | $4.4M | $8.2M | $12.7M | $8.5M | $10.2M | $8.2M |
| Cash And Cash Equivalents At Carrying Value | $22.2M | $13.6M | $14.2M | $17.0M | $4.3M | $8.1M | $8.4M | $10.2M | $8.1M | |
| Liabilities | $6.9M | $14.8M | $9.6M | $4.7M | $4.4M | $5.8M | ||||
| Assets | $36.6M | $27.3M | $28.6M | $30.7M | $18.2M | $22.9M | ||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$2.2M | -$2.8M | -$2.8M | -$3.9M | -$3.7M | -$2.4M | ||||
| Accrued Liabilities And Other Liabilities | $2.1M | $3.7M | $3.0M | $685.0K | $793.9K | $1.1M | ||||
| Retained Earnings Accumulated Deficit | -$186.4M | -$188.3M | -$178.3M | -$169.5M | -$180.7M | -$178.8M | ||||
| Restricted Cash | $79.6K | $78.6K | $74.7K | $74.0K | $82.5K | $77.7K | $81.4K | $76.9K | ||
| Liabilities Current | $2.6M | $5.1M | $4.2M | $1.6M | $2.1M | $2.6M | ||||
| Liabilities And Stockholders Equity | $36.6M | $27.3M | $28.6M | $30.7M | $18.2M | $22.9M | ||||
| Intangible Assets Net Excluding Goodwill | $4.5M | $4.6M | $4.8M | $5.0M | $5.1M | $5.3M | ||||
| Business Combination Contingent Consideration Liability Noncurrent | $1.2M | $1.2M | $1.2M | $491.8K | $580.3K | $679.3K | ||||
| Assets Current | $23.4M | $14.0M | $15.0M | $17.1M | $4.4M | $8.4M | ||||
| Accounts Receivable Net Current | $1.1M | $1.8K | $11.9K | $24.6K | $35.6K | $116.0K | ||||
| Accounts Payable Current | $520.7K | $1.4M | $1.2M | $745.3K | $1.5M | $1.3M | ||||
| Property Plant And Equipment Net | $2.6K | $2.8K | $1.6K | $1.7K | $2.0K | |||||
| Operating Lease Right Of Use Asset | $75.2K | $102.6K | $125.2K | $150.5K | $197.4K | |||||
| Operating Lease Liability Current | $85.2K | $116.3K | $121.7K | $118.5K | $129.9K | |||||
| Common Stock Value | $54.00 | $23.00 | $19.00 | $19.00 | $16.00 | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$560.5K | -$4.5M | ||||||||
| Restricted Cash Noncurrent | $74.7K | $74.0K | $82.5K | |||||||
| Other Liabilities Noncurrent | $3.6K | $3.4K | $3.4K | |||||||
| Operating Lease Liability Noncurrent | $19.3K | $49.8K | $89.5K | |||||||
| Equity | $29.7M | $12.5M | $19.0M | $26.0M | $13.7M | $17.1M | $17.5M | $17.9M | $19.5M | $17.2M |
| Cash And Cash Equivalents |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $184.4K | $814.8K | $1.3M |
| Payments Of Stock Issuance Costs | $100.0K | $1.3M | $1.1M |
| Share Based Compensation | $163.8K | $814.8K | $1.3M |
| Net Cash Provided By Used In Operating Activities | $77.2K | -$14.7M | -$14.6M |
| Net Cash Provided By Used In Financing Activities | $1.5M | $15.1M | $3.9M |
| Increase Decrease In Operating Lease Liability | -$123.3K | -$114.1K | -$107.8K |
| Increase Decrease In Deferred Liabilities | -$468.4K | -$139.2K | -$139.2K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $1.5M | $277.9K | $138.1K |
| Increase Decrease In Accounts Receivable | -$114.9K | -$299.2K | -$4.1M |
| Increase Decrease In Accounts Payable | -$917.7K | $804.4K | $374.2K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$3.8K | $77.0K | -$243.8K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$338.7K | -$174.0K | |
| Increase Decrease In Other Noncurrent Liabilities | -$2.9K | -$12.0K | $8.0K |
| Proceeds From Issuance Of Common Stock | $1.5M | $10.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $93.7K | $111.3K | $20.5K | $21.0K | $26.7K | $40.0K | $746.9K | $140.4K |
| Payments Of Stock Issuance Costs | $500.0K | $100.0K | $100.0K | $227.7K | $100.0K | $300.0K | $500.0K | |
| Share Based Compensation | $111.3K | $26.7K | $132.7K | |||||
| Net Cash Provided By Used In Operating Activities | -$3.8M | -$4.4M | -$4.4M | |||||
| Net Cash Provided By Used In Financing Activities | $3.3M | -$227.3K | $612.5K | |||||
| Increase Decrease In Operating Lease Liability | -$31.1K | -$20.3K | -$36.4K | |||||
| Increase Decrease In Deferred Liabilities | -$34.8K | -$132.2K | -$34.8K | |||||
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $718.3K | -$367.6K | -$704.7K | |||||
| Increase Decrease In Accounts Receivable | -$10.2K | -$10.9K | $16.3K | |||||
| Increase Decrease In Accounts Payable | $216.4K | -$917.7K | $880.6K | |||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$19.5K | $138.4K | -$152.8K | |||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$517.9K | -$227.7K | -$427.3K | |||||
| Increase Decrease In Other Noncurrent Liabilities | $551.00 | $331.00 | ||||||
| Proceeds From Issuance Of Common Stock | $3.3M | $700.0K | $0.00 | $6.3M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 1.6M | 832.2K | 1.47B |
| Weighted Average Number Of Diluted Shares Outstanding | 1.6M | 832.2K | 1.47B |
| Earnings Per Share Diluted | $-0.23 | $-18.62 | $-0.02 |
| Earnings Per Share Basic | $-0.23 | $-18.62 | $-0.02 |
| Common Stock Shares Issued | 1.1M | 1.47B | |
| Common Stock Shares Outstanding | 1.1M | 1.47B | |
| Common Stock Par Or Stated Value Per Share | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 4.5M | 2.2M | 1.7M | 1.6M | 1.3M | 981.0K | 857.3K | 1.50B | |
| Weighted Average Number Of Diluted Shares Outstanding | 4.5M | 2.2M | 1.7M | 1.6M | 1.3M | 981.0K | 857.3K | 1.50B | |
| Earnings Per Share Diluted | $-0.77 | $-4.41 | $6.55 | $-1.79 | $-0.62 | $-2.83 | $-5.31 | $0.00 | |
| Earnings Per Share Basic | $0.41 | $-4.41 | $6.55 | $-1.23 | $-0.62 | $-2.83 | $-5.31 | $0.00 | |
| Common Stock Shares Issued | 5.4M | 2.4M | 2.0M | 1.9M | 1.6M | 3.12B | |||
| Common Stock Shares Outstanding | 5.4M | 2.4M | 2.0M | 1.9M | 1.6M | 3.12B | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Investment Income Interest | $166.5K | $220.1K | $323.2K | |||
| Foreign Currency Transaction Gain Loss Unrealized After Tax | $168.5K | $45.2K | -$1.0M | |||
| Foreign Currency Transaction Gain Loss Realized | -$415.0K | -$209.8K | $308.9K | |||
| Fair Value Option Changes In Fair Value Gain Loss1 | $239.7K | $2.2M | -$592.6K | |||
| Stock Issued During Period Value New Issues | $1.9M | $10.1M | $3.9M | |||
| Prepaid Expense Current | $458.8K | $797.5K | ||||
| Other Noncash Income Expense | -$114.4K | -$113.5K | -$115.1K | |||
| Foreign Currency Transaction Gain Loss Before Tax | -$242.3K | $27.4K | $556.8K | |||
| Depreciation And Amortization | $662.9K | $663.0K | $663.2K | |||
| Change In Fair Value Of Contingent Consideration | $716.7K | -$1.9M | $592.6K | |||
| Additional Paid In Capital | $198.5M | $187.6M | ||||
| Warrants And Rights Outstanding | $4.7M | |||||
| Fair Value Adjustment Of Warrants | -$956.3K | -$339.0K | ||||
| Stock Issued During Period Value Stock Options Exercised | $629.00 | |||||
| Share Issue Cost | $339.5K | |||||
| Share Issued Expense Benefit | -$1.7M | -$5.7M | -$423.5K | -$48.2K | ||
| Reclassification Adjustments On Exchange Differences On Translation Net Of Tax | -$460.5K | -$1.1M | $1.2M | -$530.9K | ||
| Receipts From Sales Of Goods And Rendering Of Services | $22.0K | $271.0K | $394.8K | $4.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Investment Income Interest | $167.3K | $142.0K | $12.7K | $30.6K | $36.1K | $52.6K | $54.7K | $86.4K | |
| Foreign Currency Transaction Gain Loss Unrealized After Tax | $570.6K | $49.2K | -$195.8K | -$1.3M | $585.4K | -$561.9K | $451.1K | -$63.5K | |
| Foreign Currency Transaction Gain Loss Realized | -$135.7K | -$61.7K | $172.9K | $629.5K | -$280.0K | $216.8K | -$363.5K | -$1.6K | |
| Fair Value Option Changes In Fair Value Gain Loss1 | $5.4M | -$4.4M | -$976.7K | $805.4K | $2.9M | -$637.5K | $177.7K | -$124.6K | |
| Stock Issued During Period Value New Issues | $14.7M | $3.2M | $1.2M | $1.4M | -$22.6K | $612.5K | |||
| Prepaid Expense Current | $27.0K | $222.3K | $740.2K | $20.9K | $18.5K | $231.1K | |||
| Other Noncash Income Expense | -$27.4K | -$19.5K | -$36.2K | ||||||
| Foreign Currency Transaction Gain Loss Before Tax | -$32.6K | -$233.0K | -$67.3K | ||||||
| Depreciation And Amortization | $165.8K | $165.7K | $165.9K | ||||||
| Change In Fair Value Of Contingent Consideration | -$12.8K | $91.6K | $124.6K | ||||||
| Additional Paid In Capital | $218.3M | $203.6M | $200.2M | $199.4M | $198.2M | $198.3M | |||
| Warrants And Rights Outstanding | $2.7M | $8.1M | $3.7M | $1.9M | $810.1K | $1.7M | |||
| Fair Value Adjustment Of Warrants | $4.4M | -$3.0M | |||||||
| Stock Issued During Period Value Stock Options Exercised | $220.00 | $409.00 | |||||||
| Share Issue Cost | $111.8K | $227.7K | |||||||
| Share Issued Expense Benefit | |||||||||
| Reclassification Adjustments On Exchange Differences On Translation Net Of Tax | |||||||||
| Receipts From Sales Of Goods And Rendering Of Services |
Most recent annual filing with the SEC: September 29, 2025
Data sourced from SEC EDGAR public filings as of August 6, 2026.